Patient Release and Instructions for Lutetium Dotatate Radiopharmaceutical Therapy

Area of Science:

• Nuclear medicine
• Oncology
• Radiopharmaceutical therapy

Background:

• Lutetium Dotatate (Lutathera) is an FDA-approved radiopharmaceutical for treating somatostatin receptor-positive neuroendocrine tumors.
• Radiopharmaceutical therapies require careful management of patient radiation exposure to protect the public.

Purpose of the Study:

• To demonstrate the feasibility of outpatient administration for Lutetium Dotatate therapy.
• To establish safety and travel guidelines for patients receiving Lutetium Dotatate to enable outpatient treatment.

Main Methods:

• Analysis of radiation exposure from Lutetium Dotatate administration.
• Development of patient safety and travel restriction protocols.

Main Results:

• Lutetium Dotatate therapy can be safely administered on an outpatient basis.
• Established guidelines ensure radiation exposure to the public remains within regulatory limits.

Conclusions:

• Outpatient Lutetium Dotatate therapy is a viable treatment option for neuroendocrine tumors.
• Implementing provided safety and travel restrictions facilitates safe outpatient radiopharmaceutical treatment.